Abstract： Objective： To observe the clinical effect of warming- needle moxibustion combined with Jian'gu Yangyuan Decoction for knee osteoarthritis (KOA) of wind-cold-dampness impediment type. Methods：A total of 138 cases of patients with KOA of wind-cold and fixed impediment type were selected as research objects，and were divided into the control group and the study group according to the random number table method，with 69 cases in each group. The control group was treated with Jian'gu Yangyuan Decoction，and the study group was additionally treated with warming- needle moxibustion based on the treatment of the control group. Clinical effects，knee joint function，degree of joint pain，degree of joint stiffness， and levels of pain mediators and serum factors were compared between the two groups. Results：The total effective rate was 88.41% in the study group，higher than that of 72.46% in the control group，the difference being significant (P＜0.05). After treatment，Lyshom scores in the two groups were higher than those before treatment， and Lyshom score in the study group was higher than that in the control group (P＜0.05). After treatment，the scores of Visual Analogue Scale (VAS) and Western Ontario and McMaster Universities Arthritis Index (WOMAC) in the two groups were lower than those before treatment， and the scores of VAS and WOMAC in the study group were lower than those in the control group (P＜0.05). After treatment，the levels of prostaglandin (PGE2)，substance P (SP)，5-hydroxytryptamine (5-HT)，cartilage oligomeric matrix protein (COMP) and high mobility group protein B1 (HMGB1) in the two groups were lower than those before treatment (P＜0.05)，and the levels of PGE2，SP，5-HT，COMP and HMGB1 in the study group were lower than those in the control group (P＜0.05). Conclusion：Warmingneedle moxibustion combined with Jian'gu Yangyuan Decoction for patients with KOA of wind- colddampness impediment type can effectively relieve their clinical symptoms， help improve knee function， alleviate joint pain and stiffness，and reduce the levels of pain mediators and COMP and HMGB1 in serum.